Startups
Vesper Bio
Copenhagen, Denmark
Vesper Bio ApS is a Copenhagen clinical-stage biotechnology company developing investigational oral small-molecule sortilin inhibitors for neuropsychiatric and neurodegenerative disease. Its lead brain-penetrant candidate VES001 is being studied for frontotemporal dementia associated with progranulin-gene mutations; the company’s mechanism targets sortilin-mediated progranulin degradation. Clinical results are issuer-reported research findings, not regulatory approval or established therapeutic benefit. Its current own directory publishes fourteen staff, three external medicinal-chemistry/business-development consultants and seven scientific advisers. Founder and chief scientific officer Anders Nykjær and cofounder/chief medical officer Mads Kjølby are separately identified; Jacob Falck Hansen was appointed CEO in July2025. The Lundbeck Foundation’s audited2024 group overview lists Vesper Bio as its direct subsidiary, rather than an associate of Lundbeckfond Invest A/S. A November17,2025 USD2.5M mission-related strategic investment is attributed to ADDF and AFTD through their joint Treat FTD programme; per-buyer allocations and cash payment schedule are undisclosed. A January23,2024 MJFF award is approximately USD873000 and is not equated with cash paid. This Danish company is distinct from the unrelated Brazilian venture builder at vesper-bio.com.
Founded 2010
Team
 Adam BoxerScientific Advisor |
 Anders NykjærFOUNDER AND CSO |
 Anders RiisagerSENIOR PROJECT MANAGER |
 Andy MulvaneyExternal Business Development Consultant |
 Anna RavnefjordREGULATORY AFFAIRS SPECIALIST |
 Brittany Lo CiceroEXECUTIVE ASSISTANT AND OFFICE MANAGER |
 Eric J. HuangScientific Advisor |
 Graham WynneExternal Medicinal Chemistry Consultant |
 Henrik ZetterbergScientific Advisor |
 Imogen SwiftSENIOR RESEARCH SCIENTIST |
 James B. RoweScientific Advisor |
 John King-UnderwoodExternal Medicinal Chemistry Consultant |
 Jonathan RohrerScientific Advisor |
Jørgen Erik NielsenScientific Advisor |
 Louise KlemLEAD RESEARCH SCIENTIST |
 Lovisa SunessonDIRECTOR OF BUSINESS DEVELOPMENT |
 Lærke FensbækASSOCIATE CLINICAL TRIAL MANAGER |
 Mads KjølbyFOUNDER & CMO |
 Nina SchultzPRINCIPAL RESEARCH SCIENTIST |
 Ove PedersenSVP OF CMC & PRECLINICAL DEVELOPMENT |
 Sofie Let FrandsenSENIOR RESEARCH SCIENTIST |
 Steve FinkbeinerScientific Advisor |
 Tina VigSENIOR CLINICAL TRIAL MANAGER |
